| Followers | 200 |
| Posts | 25597 |
| Boards Moderated | 0 |
| Alias Born | 04/03/2010 |
Friday, November 26, 2021 5:47:32 PM
OK. Well I did not invest in CVM. Obviously the same nonsensical spin. No two trials are “doppelgängers”. This is nonsense.
As for whether it succeeded or failed, no idea but many seem to think it has a likelihood of approval. But they are not “doppelgängers”. That is a bunch of huey.
The game is up here because we know the game. The company appears to know the game. Many companies stupidly proceed thinking that results will convince the gamers of stock that they are wrong, but defining reality against commercial statements is an easy thing when you have writers posing as journalists who will write pieces to substantiate the claims of shorts, for whatever reason. But the reality is, their opinions do not matter in the context of scientific articles and journals. And that is the key difference with CVM.
They went the commercial announcement route. NWBO is going the journal route. So you are absolutely wrong in your comparison. And if it were as you indicate, there is no way in hell they would go the journal route first or even in the middle or last.
As for whether it succeeded or failed, no idea but many seem to think it has a likelihood of approval. But they are not “doppelgängers”. That is a bunch of huey.
The game is up here because we know the game. The company appears to know the game. Many companies stupidly proceed thinking that results will convince the gamers of stock that they are wrong, but defining reality against commercial statements is an easy thing when you have writers posing as journalists who will write pieces to substantiate the claims of shorts, for whatever reason. But the reality is, their opinions do not matter in the context of scientific articles and journals. And that is the key difference with CVM.
They went the commercial announcement route. NWBO is going the journal route. So you are absolutely wrong in your comparison. And if it were as you indicate, there is no way in hell they would go the journal route first or even in the middle or last.
Recent NWBO News
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
